[Clinical results with loperamide in the treatment of chronic diarrhoea of varied aetiology (author's transl)].
19 consecutive patients admitted with severe chronic diarrhoea which had failed to respond to standard therapeutic regimen were treated with 4 to 8 mg of loperamide daily for up to 50 weeks. A marked improvement was achieved in 13 out of the 19 patients (68%). The best results were observed in patients with ulcerative colitis and Crohn's disease. Patients with secretory diarrhoea did not improve. No major side effects were observed. It is concluded that loperamide is a highly effective and safe new drug in the treatment of patients with chronic inflammatory bowel diseases.
D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000150:complications; D002908:Chronic Disease; D003093:Colitis, Ulcerative / Q000150:complications; D003424:Crohn Disease / Q000150:complications; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D010188:Exocrine Pancreatic Insufficiency / Q000150:complications; D005260:Female; D006801:Humans; D008139:Loperamide / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D012778:Short Bowel Syndrome / Q000150:complications; D013997:Time Factors
D010880:Piperidines; D008139:Loperamide
Klinische Anwendung des neuen Antidiarrhoikums Loperamid bei chronischen Diarrhoen.